272 related articles for article (PubMed ID: 21994467)
1. Pirh2, a ubiquitin E3 ligase, inhibits p73 transcriptional activity by promoting its ubiquitination.
Wu H; Zeinab RA; Flores ER; Leng RP
Mol Cancer Res; 2011 Dec; 9(12):1780-90. PubMed ID: 21994467
[TBL] [Abstract][Full Text] [Related]
2. Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination.
Abou Zeinab R; Wu HH; Abuetabh Y; Leng S; Sergi C; Eisenstat DD; Leng RP
Carcinogenesis; 2021 Apr; 42(4):650-662. PubMed ID: 33569599
[TBL] [Abstract][Full Text] [Related]
3. MDM2 mediates p73 ubiquitination: a new molecular mechanism for suppression of p73 function.
Wu H; Leng RP
Oncotarget; 2015 Aug; 6(25):21479-92. PubMed ID: 26025930
[TBL] [Abstract][Full Text] [Related]
4. The p73 tumor suppressor is targeted by Pirh2 RING finger E3 ubiquitin ligase for the proteasome-dependent degradation.
Jung YS; Qian Y; Chen X
J Biol Chem; 2011 Oct; 286(41):35388-35395. PubMed ID: 21852228
[TBL] [Abstract][Full Text] [Related]
5. [TUMOR SUPPRESSOR p63 REGULATES EXPRESSION OF UBIQUITIN LIGASE Pirh2].
Daks AA; Petukhov AV; Shuvalov OY; Vasilieva EA; Melino G; Barlev NA; Fedorova OA
Tsitologiia; 2015; 57(12):876-9. PubMed ID: 26995965
[TBL] [Abstract][Full Text] [Related]
6. Ubiquitination-dependent degradation of p73 by the mitochondrial E3 ubiquitin ligase Hades.
Min B; Ryu J; Chi SW; Yi GS
Biochem Biophys Res Commun; 2015 Nov; 467(2):316-21. PubMed ID: 26435500
[TBL] [Abstract][Full Text] [Related]
7. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53.
Klein AM; Biderman L; Tong D; Alaghebandan B; Plumber SA; Mueller HS; van Vlimmeren A; Katz C; Prives C
Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34716260
[TBL] [Abstract][Full Text] [Related]
8. The Yes-associated protein 1 stabilizes p73 by preventing Itch-mediated ubiquitination of p73.
Levy D; Adamovich Y; Reuven N; Shaul Y
Cell Death Differ; 2007 Apr; 14(4):743-51. PubMed ID: 17110958
[TBL] [Abstract][Full Text] [Related]
9. The ubiquitin-protein ligase Itch regulates p73 stability.
Rossi M; De Laurenzi V; Munarriz E; Green DR; Liu YC; Vousden KH; Cesareni G; Melino G
EMBO J; 2005 Feb; 24(4):836-48. PubMed ID: 15678106
[TBL] [Abstract][Full Text] [Related]
10. UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination.
Hosoda M; Ozaki T; Miyazaki K; Hayashi S; Furuya K; Watanabe K; Nakagawa T; Hanamoto T; Todo S; Nakagawara A
Oncogene; 2005 Nov; 24(48):7156-69. PubMed ID: 16170377
[TBL] [Abstract][Full Text] [Related]
11. ATM engages autodegradation of the E3 ubiquitin ligase COP1 after DNA damage.
Dornan D; Shimizu H; Mah A; Dudhela T; Eby M; O'rourke K; Seshagiri S; Dixit VM
Science; 2006 Aug; 313(5790):1122-6. PubMed ID: 16931761
[TBL] [Abstract][Full Text] [Related]
12. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
Hattori T; Isobe T; Abe K; Kikuchi H; Kitagawa K; Oda T; Uchida C; Kitagawa M
Cancer Res; 2007 Nov; 67(22):10789-95. PubMed ID: 18006823
[TBL] [Abstract][Full Text] [Related]
13. Tyr99 phosphorylation determines the regulatory milieu of tumor suppressor p73.
Satija YK; Das S
Oncogene; 2016 Jan; 35(4):513-27. PubMed ID: 25893286
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.
Koida N; Ozaki T; Yamamoto H; Ono S; Koda T; Ando K; Okoshi R; Kamijo T; Omura K; Nakagawara A
J Biol Chem; 2008 Mar; 283(13):8555-63. PubMed ID: 18174154
[TBL] [Abstract][Full Text] [Related]
15. Differential control of TAp73 and DeltaNp73 protein stability by the ring finger ubiquitin ligase PIR2.
Sayan BS; Yang AL; Conforti F; Tucci P; Piro MC; Browne GJ; Agostini M; Bernardini S; Knight RA; Mak TW; Melino G
Proc Natl Acad Sci U S A; 2010 Jul; 107(29):12877-82. PubMed ID: 20615966
[TBL] [Abstract][Full Text] [Related]
16. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
Lau LM; Nugent JK; Zhao X; Irwin MS
Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
[TBL] [Abstract][Full Text] [Related]
17. p53 Activity Dominates That of p73 upon Mdm4 Loss in Development and Tumorigenesis.
Tashakori M; Zhang Y; Xiong S; You MJ; Lozano G
Mol Cancer Res; 2016 Jan; 14(1):56-65. PubMed ID: 26527653
[TBL] [Abstract][Full Text] [Related]
18. p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability.
Yan W; Zhang J; Zhang Y; Jung YS; Chen X
Mol Cell Biol; 2012 Jul; 32(13):2336-48. PubMed ID: 22508983
[TBL] [Abstract][Full Text] [Related]
19. Arsenic trioxide reactivates proteasome-dependent degradation of mutant p53 protein in cancer cells in part via enhanced expression of Pirh2 E3 ligase.
Yan W; Jung YS; Zhang Y; Chen X
PLoS One; 2014; 9(8):e103497. PubMed ID: 25116336
[TBL] [Abstract][Full Text] [Related]
20. TAp73 promotes cell survival upon genotoxic stress by inhibiting p53 activity.
Chen D; Ming L; Zou F; Peng Y; Van Houten B; Yu J; Zhang L
Oncotarget; 2014 Sep; 5(18):8107-22. PubMed ID: 25237903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
